MenC vaccination - Clinical trials 

  • Overview
  • Clinical trials
  • Clinical trials

Clinical trials for MenC vaccination

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to MenC vaccination. For all clinical trials, go to clinical trials search

This list shows clinical trials for MenC vaccination

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • MenC vaccination
Title Recruitment status Location
Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine Not recruiting United Kingdom
Understanding Immunity Persistence After Adolescent MenC Vaccination Not recruiting United Kingdom
Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine Not recruiting Poland
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents Not recruiting Costa Rica
A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the Incidence of HPV 6-, 11-, 16-, and 18-Related Genital Infection in 16- to 23-Year-Old Men - HPV Vaccine Efficacy Study in Young Men Not Recruiting Finland
A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the Incidence of HPV 6-, 11-, 16-, and 18-Related Genital Infection in 16- to 23-Year-Old Men - HPV Vaccine Efficacy Study in Young Men Not Recruiting Germany
A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the Incidence of HPV 6-, 11-, 16-, and 18-Related Genital Infection in 16- to 23-Year-Old Men - HPV Vaccine Efficacy Study in Young Men Not Recruiting Spain
A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the Incidence of HPV 6-, 11-, 16-, and 18-Related Genital Infection in 16- to 23-Year-Old Men - HPV Vaccine Efficacy Study in Young Men Not Recruiting Sweden
A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the Incidence of HPV 6-, 11-, 16-, and 18-Related Genital Infection in 16- to 23-Year-Old Men - HPV Vaccine Efficacy Study in Young Men Authorised Finland
A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the Incidence of HPV 6-, 11-, 16-, and 18-Related Genital Infection in 16- to 23-Year-Old Men - HPV Vaccine Efficacy Study in Young Men Authorised Germany
  • Link to Directgov – public services all in one place
  • The Information Standard - Certified member